ArticlePain2014
Tryptase-PAR2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome.
Article in Pain, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03167216 (Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Electrophysiological and Proteomic Evidence of Protease-Mediated Pro-nociceptive Signaling in Inflammatory Bowel Disease Patients.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Advances in immunological research on male infertility.Frontiers in reproductive health · 2026Review
- Chronic prostatitis and male infertility: association mechanism and research progress.World journal of urology · 2025Review
- Mast cell-derived chymases are essential for the resolution of inflammatory pain in mice.Pain · 2025Article
- The role of TRPV1 in chronic prostatitis: a review.Frontiers in pharmacology · 2024Review
- Autonomic Nervous System Dysfunction Is Related to Chronic Prostatitis/Chronic Pelvic Pain Syndrome.The world journal of men's health · 2024Review
- CD8 T cells are dispensable for experimental autoimmune prostatitis induction and chronic pelvic pain development.Frontiers in immunology · 2024Article
- Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition.American journal of clinical and experimental urology · 2024Review
- Efficacy of Targeted Mast Cell Inhibition Therapy in Chronic Prostatitis/Chronic Pelvic Pain Syndrome.Urology · 2023Article
- Pruritogens in pemphigoid diseases: Possible therapeutic targets for a burdensome symptom.The Journal of dermatology · 2023Review
- Microbiology and immune mechanisms associated with male infertility.Frontiers in immunology · 2023Review
- The Antifibrotic and the Anticarcinogenic Activity of Capsaicin in Hot Chili Pepper in Relation to Oral Submucous Fibrosis.Frontiers in pharmacology · 2022Review
- Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction.American journal of physiology. Renal physiology · 2021Article
- Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.International urology and nephrology · 2021Review
- mMCP7, a Mouse Ortholog of δ Tryptase, Mediates Pelvic Tactile Allodynia in a Model of Chronic Pelvic Pain.Frontiers in pain research (Lausanne, Switzerland) · 2021Article
- Involvement of Mast Cells in the Pathophysiology of Pain.Frontiers in cellular neuroscience · 2021Article
- The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain.JCI insight · 2020Article
- TRPV1 in experimental autoimmune prostatitis.The Prostate · 2020Article
- Protease-activated receptor 2 activates CRAC-mediated Ca2+ influx to cause prostate smooth muscle contraction.FASEB bioAdvances · 2019Article
- Elevated seminal plasma estradiol and epigenetic inactivation ofOncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects up to 15% of the male population and is characterized by pelvic pain. Mast cells are implicated in the murine experimental autoimmune prostatitis (EAP) model as key to chronic pelvic pain development. The mast cell mediator tryptase-β and its cognate receptor protease-activated receptor 2 (PAR2) are involved in mediating pain in other visceral disease models. Prostatic secretions and urines from CP/CPPS patients were examined for the presence of mast cell degranulation products. Tryptase-β and PAR2 expression were examined in murine EAP. Pelvic pain and inflammation were assessed in the presence or absence of PAR2 expression and upon PAR2 neutralization. Tryptase-β and carboxypeptidase A3 were elevated in CP/CPPS compared to healthy volunteers. Tryptase-β was capable of inducing pelvic pain and was increased in EAP along with its receptor PAR2. PAR2 was required for the development of chronic pelvic pain in EAP. PAR2 signaling in dorsal root ganglia led to extracellular signal-regulated kinase (ERK)1/2 phosphorylation and calcium influx. PAR2 neutralization using antibodies attenuated chronic pelvic pain in EAP. The tryptase-PAR2 axis is an important mediator of pelvic pain in EAP and may play a role in the pathogenesis of CP/CPPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.